MAIA Biotechnology, Inc. (MAIA)
$1.37-$0.05 (-3.62%) Today
Latest MAIA Insider Trades
Ramiro Guerrero - DirectorOpen-market purchase$2K
Ramiro Guerrero - DirectorRamiro Guerrero - Director
Stan Smith - DirectorStan Smith - DirectorRamiro Guerrero - DirectorMAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 5 | 163,393 | $222K |
| Grant or award | 6 | 171,935 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
66 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jean-Manasse Theagene - Director | Grant or award | Stock Options | 7,232 | $0.00 | - | |
| Stan Smith - Director | Grant or award | Stock Options | 9,040 | $0.00 | - | |
 Ngar Yee Louie - Director | Grant or award | Stock Options | 10,848 | $0.00 | - | |
| Steven M. Chaouki - Director | Grant or award | Stock Options | 7,232 | $0.00 | - | |
 Cristian Luput - Director | Grant or award | Stock Options | 7,232 | $0.00 | - | |
| Ramiro Guerrero - Director | Grant or award | Stock Options | 7,232 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 66 MAIA filings on record.
MAIA Biotechnology, Inc. (MAIA) had 11 insider filings in the last 90 days, with the most recent on 2026-08-26. The full record for MAIA runs to 66 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
5 insider purchases of MAIA were filed in the last 90 days, totaling $222K.
No insider sales of MAIA were filed in the last 90 days.
This page tracks MAIA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add MAIA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
